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Abstract: Although radiotherapy is a common form of treatment for head and neck cancer, it may 
lead to tissue damage in the salivary and lacrimal glands, possibly affecting cytokine expression in 
the gland fluid of treated individuals. Cytokine profiles in saliva and tear fluid of 29 radiated head 
and neck cancer patients and 20 controls were screened using a multiplex assay. Correlations 
between cytokine expression and clinical oral and ocular manifestations were examined, and 
cellular pathways influenced by these cytokines were assessed using the Functional Enrichment 
Analysis Tool. Significantly elevated cytokines identified in patient saliva were CCL21, IL-4, 
CX3CL1, CCL2, CXCL1 and CCL15. Many of these cytokines correlated positively with objective 
signs of oral dryness, and reduced saliva production in the patients. Although CCL21 and IL-4 levels 
were significantly lower in patient tear fluid, they correlated with subjective ocular symptoms. 
These increased salivary cytokines affected pro-inflammatory and apoptotic cellular pathways, 
including T cell signalling, several interleukin signalling pathways, TNF and TGF-β receptor 
signalling, and the apoptotic p53 pathway. In conclusion, the upregulated salivary cytokines 
identified suggest an interplay between innate and adaptive immunity, affecting immunoregulatory 
cellular pathways. Whether this is due to late effects of radiotherapy or tissue repair remains to be 
investigated. 
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Head and neck cancer constitutes a group of cancers located in the pharynx, larynx, oral cavity, 
sino-nasal cavities and salivary glands [1]. Symptoms depend on the tumour location and include a 
lump and/or sore throat, and/or a mucosal ulceration that does not heal, trouble swallowing, voice 
change, unusual bleeding, facial swelling, numbness, and difficulty breathing [2]. It is the sixth most 
common cancer in the world, being responsible for 1–2% of tumour deaths worldwide [3]. When it 
comes to malignancies of the head and neck area, oral- and oropharyngeal cancers are the most 
prevalent, where squamous cell carcinoma represents more than 90% of such cases [4]. 
When treating head and neck cancers, radiotherapy is often employed, either alone or in 
combination with surgery [5–8]. In order to reduce normal tissue toxicity, the use of intensity-
modulated radiotherapy has been implemented [9]. This technique maximises delivery to the 
targeted tissue, and minimises the dose to the surrounding healthy tissue [10]. Factors other than the 
radiotherapy technique used may also contribute to adjacent normal tissue damage, such as damage 
to the salivary and lacrimal glands [11]. These include radiation doses above 15–20 Gy, the 
localisation of the tumour and the volume of the targeted tissue [12]. 
Radiotherapy of head and neck cancer may damage salivary and lacrimal gland function, 
resulting in decreased saliva and tear production and symptoms such as dry mouth and dry eyes in 
patients. Despite decades of research, the pathogenic mechanisms associated with ocular and oral 
dryness are still not fully understood. Clinical tools that are implemented for measuring oral and 
ocular signs are often susceptible to subjective interpretation. In contrast, protein analysis has the 
advantage of being less prone to such subjective bias [13]. Inflammatory cytokine levels are expected 
to be elevated in fluids from affected glands [14]. Cytokines are intercellular signalling proteins that 
play a role in regulating cell growth, cellular proliferation, angiogenesis, tissue repair, and immune 
responses to infection, injury and inflammation [15]. Therefore, saliva and tear fluid may contain 
valuable biomarkers for diagnostic and therapeutic purposes [16]. Advances in the technology of 
multiplex bead arrays have allowed this technique to be applied in identifying proteins of low 
abundance in small sample volumes, while also demonstrating consistency with findings from ELISA 
assays [17,18]. These verifications make multiplex immunobead assays an attractive method for 
studying saliva and tear fluid from patients treated with radiotherapy. 
Previous studies have described several salivary cytokines detected 1-3 weeks after radiotherapy 
in head and neck cancer patients [19–23]. The studies utilised both multiplex bead-based 
immunoassays and ELISA to identify pro- and anti-inflammatory cytokines, such as interleukin (IL)-
1α, IL-1β, IL-4, IL-6, IL-8, IL-10, MCP-1, and TNF-α. These elevated cytokine levels also correlated 
with the radiation dose. Interestingly, in several oral and systemic conditions, including periodontal 
disease, Sjögren’s syndrome, and rheumatoid arthritis, levels of inflammatory cytokines are shown 
to increase in saliva [24]. We have previously explored cytokine levels in saliva and tear fluid from 
primary Sjögren’s syndrome patients in the search for disease-specific biomarkers. Our results 
demonstrated elevated levels of IP-10 and MIP-1a in saliva, and IL-1ra, IL-2, IL-4, IL-8, IL-12p70, IL-
17A, IFN-γ, IP-10, MIP-1b, and RANTES in tear fluid [14]. 
To date, limited work has been published related to the concurrent investigation of cytokine 
profiles in saliva and tear fluid from radiated head and neck cancer patients. It is assumed that an 
interdisciplinary approach could increase the knowledge basis and lead to a better evaluation of late 
effects in these patients. Hence, in the present study, we aimed to investigate how late effects of 
radiotherapy might influence cytokine profiles, oral and ocular clinical outcomes, and 
immunoregulatory cellular pathways, in the saliva and tear fluid of radiated head and neck cancer 
patients, explored at least 6 months after radiation treatment. Our results demonstrate enhanced 
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cytokine levels that suggest an interplay between innate and adaptive immune responses, affecting 
immunoregulatory cellular pathways, and notably, correlating with oral manifestations and ocular 
symptoms. 
2. Materials and Methods 
Study participants. This study was performed in compliance with the tenets of the Declaration 
of Helsinki, in the period September 2018 to March 2019. The participants included 29 patients 
diagnosed with head and neck cancer who had completed intensity-modulated radiotherapy 
treatment at least 6 months prior to recruitment, and 20 age- and sex-matched healthy individuals 
with no complaints of dry mouth or dry eyes. Written informed consent was obtained from all 
participants, and the Regional Medical Ethical Committee of South-East Norway approved the study 
(2018/1313). 
All recruited patients had undergone radiotherapy for head and neck cancer, at the Department 
of Oncology, Oslo University Hospital, Norway. Fourteen patients had been treated with primary 
radiotherapy, receiving a total dose of 68–70 Gy, and fifteen patients had received postoperative 
radiotherapy with a total dose of 50–66 Gy. The average radiation dose to the parotid gland was 23.1 
± 10.2 Gy (range, 1.6 to 48.5 Gy), and to the lacrimal gland 1.8 ± 4.2 Gy (range, 0.3 to 17.5 Gy). The 
radiotherapy was delivered as 2 Gy per fraction, administered 5–6 times per week, in accordance 
with standard treatment guidelines. The treatment volume varied according to tumour localisation 
and extension. In accordance with treatment guidelines, no shield was used to protect the lacrimal 
gland or the eye, since treatment volumes were distant from the eye. Furthermore, concomitant 
chemotherapy was given to patients under 70 years of age as part of the primary treatment for stage 
III-IV disease, or as part of the post-operative treatment in cases where there was marginal or 
perinodal infiltration. A total of twelve patients received concurrent cisplatin or cetuximab, every 
week for 3–6 weeks. The distribution of tumour location of the patients is shown in Figure 1, while 
patient demographics are presented in Table 1. 
 
Figure 1. Disease location in patients with head and neck cancer (n = 29). 
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Table 1. Clinical characteristics of patients included in the study. 
Patient No. Age Sex 
Smoking 
Status 
Type of Radiotherapy Treatment * 




1 54 Male No Primary 68 + 
2 75 Male No Primary 68 − 
3 63 Female No Primary 70 + 
4 82 Female No Primary 68 − 
5 61 Male No Primary 68 + 
6 70 Male No Primary 68 + 
7 69 Female Yes Primary 68 − 
8 58 Male No Primary 68 + 
9 67 Male No Primary 68 + 
10 59 Male Yes Primary 68 − 
11 53 Male No Primary 68 + 
12 64 Male No Primary 68 + 
13 57 Male Yes Primary 68 + 
14 68 Male No Primary 68 + 
15 73 Male No Postoperative 56 − 
16 66 Female No Postoperative 66 − 
17 65 Female No Postoperative 60 − 
18 73 Female No Postoperative 66 − 
19 71 Female No Postoperative 60 − 
20 66 Female No Postoperative 66 − 
21 51 Female Yes Postoperative 66 − 
22 58 Male No Postoperative 60 - 
23 41 Female Yes Postoperative 60 + 
24 82 Male No Postoperative 60 − 
25 51 Female No Postoperative 60 + 
26 65 Female No Postoperative 66 − 
27 58 Male No Postoperative 60 − 
28 60 Female Yes Postoperative 50 − 
29 82 Male No Postoperative 60 − 
* All patients received radiotherapy. Some received radiation alone (primary), while others 
underwent excision surgery prior to radiation (postoperative). 
Clinical evaluation of oral and ocular dryness. Upon recruitment it was verified that all 
radiated head and neck cancer patients were currently cancer free. Individuals in the control group 
had no history of dry mouth/dry eye complaints, no systemic disorders or diseases with potential 
oral and/or ocular involvement, no previous surgery, and no use of medications that may affect 
lacrimal and salivary gland secretion. The oral examinations were performed at the Dry Mouth 
Clinic, Institute of Clinical Dentistry, Faculty of Dentistry, University of Oslo, Oslo, Norway, while 
the clinical ocular evaluations were performed at the Norwegian Dry Eye Clinic, Oslo, Norway, as 
described previously [25,26]. Participants were asked not to have anything in the mouth for at least 
1 h before their oral assessment, and to avoid using any eye drops at least 2 h prior to their eye 
examination. 
At the Dry Mouth Clinic, the Summated Xerostomia Inventory-Dutch Version (SXI-D) [27] 
questionnaire with a sum score (range: 5–15) was used to determine the severity of subjective feelings 
of xerostomia. The Clinical Oral Dryness Score (CODS) index was used to acquire an objective clinical 
score (range: 0–10) for oral dryness [28]. Moreover, the presence of candida growth was assessed, and 
unstimulated whole saliva (UWS) and chewing-stimulated whole saliva (SWS) samples were 
collected, as previously described [25]. Since saliva composition may be influenced by the circadian 
rhythm, sample collection was performed between 10:00 a.m. and 14:30 p.m. The SWS samples were 
aliquoted and stored at −80 °C until further cytokine analysis. 
At the Norwegian Dry Eye Clinic, the severity of subjective dry eye symptoms was evaluated 
using the Ocular Surface Disease Index (OSDI) questionnaire. This was followed by tear quality 
evaluation using tear film break-up time (TFBUT) after instillation of 5 µL of 2% fluorescein sodium 
in each eye. Grading of corneal staining (CS) (range: 0–5) and bulbar conjunctival (ocular surface) 
staining (OSS) (range: 0–15) with fluorescein was recorded according to the Oxford scoring scheme 
[29]. Tear production was measured using Schirmer’s test, while assessment of the meibomian gland 
(MG) functionality and meibomian gland expressibility (ME) were assessed, as previously described 
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[26]. Meibography images were obtained using the non-contact infrared camera system Oculus 
Keratograph 5 after eversion of the eyelids: meibomian gland dropout score (MGDS) in upper (UL) 
and lower (LL) lids was evaluated using a four-point grading scale (meiboscore) from 1 to 4 
(meiboscore 1: 0–25% area loss of MG; score 2: 26–50% area loss of MG; score 3: 51–75% area loss of 
MG; and score 4: area loss over 75%). Tear fluid was collected using the Schirmer’s tear test strip 
(Haag-Streit, Essex, UK). Each Schirmer strip was transferred to an Eppendorf tube containing 500 
µL of 0.1 µm filtered phosphate-buffered saline (PBS) pH 7.4 (Gibco, ThermoFisher Scientific, Oslo, 
Norway), and stored at −80°C until cytokine analysis. 
Cytokine profiling of saliva and tear fluid. Cytokine concentrations in the saliva and tear fluid, 
collected from all 29 patients and 20 controls, were measured using immunoassay technology (Bio-
Plex xMap; Luminex Corp., Austin, TX, USA) with the commercial instrument Luminex IS 200 (Bio-
Rad Laboratories, Inc., Hercules, CA, USA). Prior to analysis, Eppendorf tubes with Schirmer strips 
stored in PBS were thawed on ice and vortexed. Tear fluid and saliva samples were transferred into 
fresh tubes and diluted five folds with PBS containing BSA (final BSA concentration 0.5%). All 
samples were centrifuged at 10,000× g for 10 min at 4 °C, and 25 µL of the supernatant were then 
loaded onto 96-well plates. 
The multiplex analysis was performed according to a previously published protocol [30]. The 
broad screening kit was used for the analysis (Bio-Plex Pro Human Cytokine 40-plex Assay, Cat. No. 
171AK99MR2, Bio-Rad Laboratories, Inc.) and included targets against: CCL21, CXCL13, CCL27, 
CXCL5, CCL24, CCL26, CCL11, CX3CL1 (also known as fractalkine), CXCL6, GM-CSF, CXCL1, 
CXCL2, CCL1, CXCL11, IFN-γ, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, CCL2 (also referred to 
as MCP-1), MCP-2, MCP-3, MCP-4, CCL22, MIF, CXCL9, MIP-1, CCL15 (also called MIP-1δ), MIP-
3, MIP-3, CCL23, CXCL16, CXCL12, CCL17, CCL25, and TNF-. 
All values obtained from the assay were in an acceptable range according to recommendations 
from the manufacturer (intra-percent coefficient of variation <11 and inter-percent coefficient of 
variation >21). Total protein concentrations in the Schirmer strip suspensions and saliva were 
estimated using the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA) and were 
expressed as mg/mL. The levels of cytokines were adjusted with total protein concentration and 
expressed as (pg of cytokine)/(mg of total protein). 
Data processing and statistical analyses. Statistical analyses were performed using SPSS 
software version 25.0 (IBM Corporation, Armonk, NY, USA). Reported results were presented as 
means ± standard deviation. The Shapiro–Wilk test was used to assess the normality of the variables. 
The Mann–Whitney U test was applied to determine whether there was any statistical significance 
between patients and controls. Associations of cytokine levels with numerical clinical parameters and 
radiation dosages were determined using Spearman rank correlation. In all analyses, a p-value of < 
0.05 was considered significant. 
For functional analysis of the cytokine data, the Functional Enrichment Analysis Tool (FunRich) 
(http://www.funrich.org/) was applied to visualise the percentage of significantly upregulated 
cytokines involved in each of the affected signalling pathways.  
3. Results 
3.1. Elevated Levels of Immunoregulatory Cytokines Detected in the Saliva of Radiated Head and Neck 
Cancer Patients Correlated with Clinical Oral Manifestations  
Through the application of multiplex assay analysis, we were able to perform a broad screening 
of cytokines in saliva of radiated head and neck cancer patients as compared to healthy individuals. 
Our results revealed significantly higher levels of CCL21, CX3CL1, CXCL1, IL-4, CCL2, and CCL15 
in the patient group when compared to healthy controls (Figure 2). The patients also had more 
subjective oral complaints, showing higher SXI-D questionnaire scores, than the healthy controls. 
Clinical examinations showed that the patients had a significantly higher mean objective oral dryness 
than controls as shown by the CODS index [28]. In addition, compared to healthy controls, the 
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patients had lower unstimulated and stimulated whole saliva secretion rates, and higher candida 
counts (Figure 3).  
When viewed as a whole, the levels of upregulated cytokines correlated significantly with 
clinical dry mouth findings, but not with smoking status, treatment with chemotherapy, total 
radiation dose, nor with radiation dose administered to the parotid glands. More specifically, the 
level of CX3CL1 correlated with CODS (r = 0.486, p < 0.009) and UWS secretion rate (r = −0.420, p < 
0.026). The level of CXCL1 was correlated with SXI (r = 0.417, p < 0.027), CODS (r = 0.760, p < 0.0001), 
UWS secretion rate (r = −0.433, p < 0.021), and SWS secretion rate (r = −0.394, p < 0.038). Similarly, IL-
4 correlated with CODS (r = 0.595, p < 0.001) and UWS secretion rate (r = −0.490, p < 0.008), while 
CCL15 levels only corresponded with CODS (r = 0.511, p < 0.005). A more detailed representation of 
the relationship between summed CODS scores and the concentrations of upregulated salivary 
cytokines detected in each patient are presented in Table 2. 
 
Figure 2. Elevated cytokine levels in the saliva of radiated head and neck cancer patients and healthy 
controls. Multiplex assay measurement of the cytokine levels in the patients’ saliva after radiotherapy 
revealed significantly higher levels of CCL21, CX3CL1, CXCL1, IL-4, CCL2, and CCL15, when 
compared to the controls. * represents p < 0.05; ** represents p < 0.01. 
 
Figure 3. Clinical oral evaluations in patients and controls. Radiated head and neck cancer patients 
displayed significantly higher mean oral dryness score compared to the healthy controls in terms of 
both the subjective Summated Xerostomia Inventory (SXI) questionnaire and the objective Clinical 
Oral Dryness Score (CODS). Moreover, the patients showed lower unstimulated whole saliva (UWS) 
and stimulated whole saliva (SWS) production, and higher candida counts. SXI: Summated 
Xerostomia Inventory questionnaire score; CODS: Clinical Oral Dryness Score index; UWS: 
unstimulated whole saliva secretion rate (ml/min); SWS: stimulated whole saliva secretion rate 
Cells 2020, 9, 2050 7 of 13 
 
(ml/min). The x-axis includes the clinical oral evaluations conducted. The y-axis illustrates the 
different scores attained from these examinations. * represents p < 0.05; *** represents p < 0.001. 
Table 2. Summed CODS scores vs. concentration of upregulated salivary cytokines identified in head 
and neck cancer patients. 
Sum CODS * CXCL 1 ** IL-4 ** CCL 15 ** CCL21 ** CX3CL1 ** CCL2 ** 
8 551 12 83 418 488 163 
8 570 15 40 258 242 70 
8 546 8 26 162 213 52 
8 424 1 36 112 172 50 
8 1252 11 44 256 437 143 
8 200 0 37 348 213 195 
7 270 5 21 327 314 136 
7 235 0 26 303 221 135 
7 274 2 15 202 358 160 
7 82 0 13 305 185 202 
7 264 0 10 243 221 154 
7 290 0 38 190 300 71 
6 245 9 21 417 442 160 
6 51 0 13 192 186 111 
6 123 6 30 238 255 98 
6 11 0 3 0 97 18 
6 266 0 20 211 183 100 
6 102 0 8 147 271 123 
5 72 0 18 0 126 28 
5 1503 11 124 389 748 211 
4 152 4 24 141 331 54 
4 56 0 5 133 129 47 
4 228 0 12 256 507 162 
3 37 0 16 173 137 47 
3 188 0 14 188 142 65 
3 68 0 41 167 100 24 
3 158 0 6 181 125 139 
2 118 0 9 164 168 49 
* The Clinical Oral Dryness Score index (CODS), ranging from 0 to 10, is arranged in descending 
order, where the highest score has the darkest colour and the lowest score has the lightest colour. ** 
The concentrations of upregulated cytokines (ng cytokine per mg total protein) detected in each 
patient’s saliva are shown, with the highest concentrations having the darkest colour, and the lowest 
concentration having the lightest colour. 
3.2. Cytokines Detected in the Tear Fluid of Radiated Head and Neck Cancer Patients Correlated with 
Clinical Ocular Symptoms 
In tear fluid, the cytokine profiling analysis showed that levels of CCL21 and IL-4 were 
significantly lower in the patient group than in the control group (Figure 4). Other cytokine levels 
did not show statistically significant differences between patients and controls. However, regarding 
the dry eye evaluation, the patients had more severe subjective dry eye symptoms, as shown by a 
higher OSDI score than the controls. The MGDS_UL was also significantly higher in the patients, 
whereas other ocular examinations did not demonstrate statistically significant differences between 
the two groups (Figure 5). When comparing the two downregulated cytokines in tear fluid with 
clinical dry eye tests, levels of CCL21 showed significant correlations with OSDI score (r = 0.385, p < 
0.047) and ME (r = 0.488, p < 0.010), but not with other dry eye tests, smoking status, treatment with 
chemotherapy, nor radiation dose. 
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Figure 4. Comparison of cytokine levels in the tear fluid of radiated head and neck cancer patients 
and controls. Multiplex assay of the cytokine levels in tear fluid reveal significantly lower levels of 
both CCL21 and IL-4 in the patient group as compared to the controls. Other cytokine levels do not 
show statistically significant differences between patients and controls. * represents p < 0.05. 
 
Figure 5. Clinical dry eye tests in patients and healthy individuals. Radiated patients show 
significantly more severe subjective dry eye symptoms when compared to controls, as indicated by a 
higher Ocular Surface Disease Index (OSDI) score, and significantly higher meibomian gland dropout 
score on the upper lid (MGDS_UL). Other ocular examinations do not exhibit statistically significant 
differences between the two groups. OSDI: Ocular Surface Disease Index questionnaire score; TFBUT: 
tear film breakup time; OSS: ocular surface staining; CS: corneal staining; ME: meibomian gland 
expressibility; MQ: meibum quality; MGDS: meibomian gland dropout score; UL: upper lid; LL: lower 
lid. The x-axis includes the clinical ocular evaluations conducted. The y-axis illustrates the different 
scores attained from these examinations. * represents p < 0.05. 
3.3. Cytokines Detected in Radiated Head and Neck Cancer Patients Affected Pro-Inflammatory and 
Apoptotic Cellular Pathways 
After identifying significantly elevated cytokines in saliva, we wished to investigate which 
cellular pathways were affected by these particular cytokines. For such functional analysis of the 
cytokine data the FunRich analysis tool was applied, and the fraction of elevated cytokines 
influencing each of the cellular pathways detected was also estimated (presented as percentages). 
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These pathways involved T cell JNK, and CD40/CD40L signalling (20%). Moreover, signalling 
pathways mediated by IL-1 (20%), IL-2 (20%), IL-3 (60%), IL-4 (20%), IL-5 (60%), IL-12 (20%), and IL-
23 (40%) were also affected, in addition to TNF and TGF-β receptor signalling (20%). Finally, the 
apoptotic p53 pathway (20%) was also influenced by upregulated salivary cytokines (Figure 6). 
 
 
Figure 6. Elevated cytokine levels in saliva of radiated head and neck patients affected pro-
inflammatory and apoptotic cellular pathways. The FunRich analysis of cytokines that were 
significantly upregulated in the saliva samples from the patients revealed which cellular pathways 
were influenced by these elevated cytokines, and the fractions of total upregulated cytokines that 
were involved in affecting these different cellular pathways. These included T cell JNK (20%), and 
CD40/CD40L (20%) signalling, IL-1 (20%), IL-2 (20%), IL-3 (60%), IL-4 (20%), IL-5 (60%), IL-12 (20%), 
and IL-23 (40%) signalling, in addition to TNF (20%) and TGF-β (20%) receptor signalling, and finally 
the apoptotic p53 pathway (20%). 
4. Discussion 
The present study marks the first time cytokine profiles were simultaneously explored in the 
saliva and tear fluid of patients with head and neck cancer post-radiotherapy. In spite of our patient 
group being rather small and heterogenous, representing subjects with primary and adjuvant 
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radiotherapy (with and without chemotherapy), we identified significantly elevated cytokines in the 
saliva that have not been reported previously. This could be explained by the timing of the sample 
collection. In order to explore the late effects of radiotherapy, we recruited patients for cytokine 
analyses at least 6 months after treatment, while cytokine screening in previous reports had been 
conducted already 1–3 weeks after radiotherapy [19–23]. Therefore, the upregulated cytokines 
discovered in the present study could be part of a biological reaction to radiotherapy that may be 
associated with late effects, as indicated by the immunoregulatory and apoptotic cellular pathways 
identified [20]. However, their overexpression could also be due to tissue repair following 
radiotherapy. Radiation doses above 15–20 Gy, and treatment involving a larger volume of the 
targeted tissue could contribute to more severe damage to the glands [11], which may in turn trigger 
tissue repair mechanisms. The patients in this study received a total radiation dose of 64.5 ± 4.8 Gy 
(range 50 to 70), with a stronger average radiation dose directed to the saliva-producing parotid 
glands (23.1 ± 10.2 Gy, range 1.6 to 48.5), than to the smaller tear-producing lacrimal glands (mean 
1.8 ± 4.2 Gy, range 0.3 to 17.5). In this respect, tear fluid measurements could be viewed as a control 
for the influence of radiotherapy, since only modest radiation doses were applied to the lacrimal 
glands, and our objective ocular examinations did not detect a pertinent difference between patients 
and controls. Notably, more prominent oral manifestations were observed in the patients, as 
compared to ocular findings. 
Out of the six significantly elevated cytokines found when screening the saliva of these patients, 
CCL21 and IL-4 were significantly lower in the patients’ tear fluid than in the control participants. 
This may have been due to the anti-inflammatory roles of CCL21 and IL-4 in regulating disease 
progression. One function of CCL21 is to guide CCR7-expressing naïve T cells to T cell zones in the 
lymph nodes [31–33]. It is noteworthy that for most of the patients receiving radiotherapy to their 
parotid glands, the radiation field also covered the lymph nodes in the upper neck region. Hence, 
elevated levels of CCL21 in the saliva of the patients could be a result of tissue repair [31]. On the 
other hand, reduced CCL21 levels in the tear fluid of these same individuals could be a consequence 
of the lower radiation dose administered to their lacrimal glands, in turn leading to less tissue 
damage. This explanation is also supported by the fact that the objective ocular examinations did not 
exhibit statistically significant differences in results when comparing the patient group to the healthy 
controls. Furthermore, a positive correlation was only shown with the symptom-assessing ocular 
surface damage questionnaire (r = 0.385, p < 0.047), and expression ability of the meibomian glands 
in the eyelids (r = 0.488, p < 0.010). This further explains why the lower radiation dose administered 
to the lacrimal glands could have resulted in less severe clinical ocular manifestations. 
The high level of IL-4 in saliva of the head and neck cancer patients in this study was consistent 
with a previous study by Citrin et al., who also found the expression levels to be dependent on the 
radiation dose [20]. Furthermore, IL-4 levels also correlated with clinical oral dryness scores (r = 0.595, 
p < 0.001) and unstimulated saliva secretion rates (r = −0.490, p < 0.008) in the patient group. 
Considering that IL-4-mediated cellular pathways were also affected in the FunRich analysis, this 
emphasises the central role of this cytokine in humoral immunity, by inducing differentiation of naïve 
helper T cells to Th2 cells (CD4 + Th cells), which in turn plays a central role in regulating B cell 
activation [20,34]. 
Other significantly elevated cytokines detected in the saliva of head and neck cancer patients 
included CX3CL1, CCL2, CXCL1 and CCL15, most of which correlated with UWS secretion rates and 
objective oral dryness (CODS). In particular, CXCL1 exhibited the highest concentrations that 
correlated strongly with high CODS values (r = 0.760, p < 0.0001), while other cytokines also displayed 
an evident association between cytokine levels in saliva and CODS, as illustrated in the colour scheme 
of Table 2. This further suggests a relationship between objective signs of oral dryness and cytokine 
production in these radiated head and neck cancer patients, a finding that exhibits relatively long 
after radiotherapy treatment. 
Among the significantly elevated salivary cytokines identified, the CX3CL1 chemokine is known 
to induce chemotaxis of monocytes and cytotoxic T cells, while itself being a direct target of the 
tumour suppressor protein p53 [35]. Interestingly, the p53 pathway was one of the affected cellular 
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pathways identified in the FunRich analysis, suggesting enhanced tumour suppression and apoptosis 
in the treated patients. Similarly, CCL2, also referred to as monocyte chemoattractant protein 1 (MCP-
1), recruits monocytes, memory T cells, and dendritic cells to the sites of inflammation [36,37], as 
indicated in the CD40/CD40L cellular pathway identified in our study. MCP-1 has previously been 
detected in the saliva of head and neck cancer patients [19] soon after radiation therapy, and it 
remained significantly elevated in our analysis at a later time point. Meanwhile, CXCL1, expressed 
by macrophages, in addition to neutrophils and epithelial cells, plays a role in the processes of 
angiogenesis, tumorigenesis, inflammation, and wound healing [38,39]. Interestingly, it has been 
reported that when head and neck cancer patients with squamous cell carcinoma develop metastases, 
66% of these metastases are situated in the pulmonary tissue [40]. This is also in line with the elevated 
levels of CCL15 in the saliva of our patient group, since this pro-inflammatory chemokine can also 
be expressed by macrophages in the lung tissue [41,42]. 
In conclusion, we have demonstrated that upregulated cytokines, particularly those identified 
in the saliva of radiated head and neck cancer patients, imply an interplay between innate and 
adaptive immune responses, affecting immunoregulatory cellular pathways, and importantly, 
correlating with oral manifestations and ocular symptoms. Whether these elevated cytokines are the 
result of late effects of treatment or the repair process remains to be explored in a larger and less 
heterogenous cohort in future follow-up studies. 
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